Une nouvelle étude sur des milliards de doses de vaccins à ARNm confirme leur sécurité et leur efficacité

A recent comprehensive study published in The Lancet has confirmed the safety and efficacy of more than 13 billion doses of mRNA vaccines administered worldwide since their introduction in late 2020. This global rollout began in the United States through Operation Warp Speed, which was initiated under the first Trump administration. The study, conducted by an international team of researchers, analyzed data from randomized clinical trials, post-authorization monitoring, and ongoing pharmacovigilance systems to evaluate the performance of these vaccines over the past six years. The research highlights that serious adverse side effects from mRNA vaccines remain extremely rare. One notable concern raised has been the increased risk of myocarditis—specifically an inflammation of the heart—among young males following vaccination. According to the findings, the incidence rates were approximately 12.6 cases and 35.6 cases per million for Pfizer-BioNTech’s and Moderna’s vaccines, respectively. Despite this, the study points out that the risk of developing myocarditis from a COVID-19 infection itself is significantly higher, ranging between 20 to 42 times greater than the risk associated with vaccination. Moreover, the incidence of myocarditis linked to updated versions of the mRNA vaccines does not exceed the general background rate observed in the population. The study also emphasizes the high effectiveness of mRNA vaccines in preventing SARS-CoV-2 infections and related severe outcomes. Across various clinical trials and real-world data, the vaccines demonstrated about 87% effectiveness against any documented infection, 93% against hospitalization, and 94% against mortality within 14 to 42 days after receiving the shot. While effectiveness decreased over time and varied depending on factors such as age and the presence of specific viral variants like Omicron, booster doses were shown to help restore protective immunity levels. Beyond their role in combating the current pandemic, the review explores the potential applications of mRNA vaccine technology in treating and preventing other health conditions. These include influenza, respiratory syncytial virus (RSV), cancer, and autoimmune disorders. Recent developments in this area include the endorsement by the Food and Drug Administration (FDA) advisory committee of a new Moderna mRNA-based influenza vaccine intended for individuals aged 50 and above. This vaccine was previously stalled due to concerns raised by Vinay Prasad, who was then leading the Center for Biologics Evaluation and Research at the FDA. The advisory panel highlighted that the new vaccine elicits a broader immune response compared to traditional seasonal flu vaccines and targets multiple strains of the influenza virus. A final decision regarding its approval is anticipated in August. Currently, there are at least 120 clinical trials underway aimed at developing mRNA vaccines for various types of cancer. These efforts underscore the adaptability and versatility of mRNA technology beyond its initial application in addressing the SARS-CoV-2 virus. The conclusion drawn by the researchers in The Lancet reaffirms the established safety profile and effectiveness of mRNA vaccines. They assert that these vaccines represent a reliable and flexible platform with continued significance for future infectious disease prevention and overall public health readiness. As research continues to evolve, the potential for expanding the use of mRNA vaccines into new therapeutic areas remains promising, offering hope for innovative approaches to tackling a wide range of medical challenges.